bacteriophage-derived vectors for targeted cancer gene therapy
Clicks: 282
ID: 209712
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
282 views
51 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #108 of 245 articles by views in International journal of pharmaceutics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Cancer gene therapy expanded and reached its pinnacle in research in the last decade. Both viral and non-viral vectors have entered clinical trials, and significant successes have been achieved. However, a systemic administration of a vector, illustrating safe, efficient, and targeted gene delivery to solid tumors has proven to be a major challenge. In this review, we summarize the current progress and challenges in the targeted gene therapy of cancer. Moreover, we highlight the recent developments of bacteriophage-derived vectors and their contributions in targeting cancer with therapeutic genes following systemic administration.
| Reference Key |
pranjol2015virusesbacteriophage-derived
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Md Zahidul Islam Pranjol;Amin Hajitou |
| Journal | International journal of pharmaceutics |
| Year | 2015 |
| DOI |
10.3390/v7010268
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.